These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 17242144

  • 1. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.
    Boak LM, Li J, Rayner CR, Nation RL.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1287-92. PubMed ID: 17242144
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL, Kiffer CR, Mendes CM, Nicolau DP.
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.
    Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH.
    J Antimicrob Chemother; 2007 Oct; 60(4):819-23. PubMed ID: 17673476
    [Abstract] [Full Text] [Related]

  • 6. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H.
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A.
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
    Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D.
    J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.
    Wiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE.
    J Antimicrob Chemother; 2005 May; 55(5):792-5. PubMed ID: 15814598
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ.
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 14. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G, White R, Friedrich L.
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [Abstract] [Full Text] [Related]

  • 15. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
    Gonzalez N, Sevillano D, Alou L, Cafini F, Gimenez MJ, Gomez-Lus ML, Prieto J, Aguilar L.
    J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
    [Abstract] [Full Text] [Related]

  • 16. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H, Xie J, Chen L, Wang T, Sun J, Zhao Y, Dong Y.
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [Abstract] [Full Text] [Related]

  • 17. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE, Fritsche TR, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [Abstract] [Full Text] [Related]

  • 19. [Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
    Jankowski A, Stefanik W.
    Wiad Lek; 2006 Jun; 59(9-10):727-31. PubMed ID: 17338140
    [Abstract] [Full Text] [Related]

  • 20. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro.
    Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Møller N.
    J Antimicrob Chemother; 2010 May; 65(5):962-73. PubMed ID: 20211859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.